Evidence map›Paper›PMID 33097836›Full record

ReviewThe Journal of antibiotics2021

Recent progress in biodiversity research on the Xylariales and their secondary metabolism.

Kevin Becker, Marc Stadler

Abstract readReview
In one paragraph

Review in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed.

  1. Article
  2. Curtachalasins Y1-Y13, Anti-Inflammatory Cytochalasans from the Soil FungusInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Unearthing a fungal giant:Frontiers in fungal biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Lienhwalides: Unique Tropolone-Maleidride Hybrids from Hypoxylon lienhwacheense.Chembiochem : a European journal of chemical biology · 2025
    Article
  16. Biopesticide Compounds from an Endolichenic FungusMolecules (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Two new species ofMycoKeys · 2025
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kevin BeckerDepartment Microbial Drugs, Helmholtz Centre for Infection Research GmbH, Inhoffenstraße 7, 38124, Braunschweig, Germany.
Marc StadlerDepartment Microbial Drugs, Helmholtz Centre for Infection Research GmbH, Inhoffenstraße 7, 38124, Braunschweig, Germany. marc.stadler@helmholtz-hzi.de.ORCID http://orcid.org/0000-0002-7284-8671

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The families Xylariaceae and Hypoxylaceae (Xylariales, Ascomycota) represent one of the most prolific lineages of secondary metabolite producers. Like many other fungal taxa, they exhibit their highest diversity in the tropics. The stromata as well as the mycelial cultures of these fungi (the latter of which are frequently being isolated as endophytes of seed plants) have given rise to the discovery of many unprecedented secondary metabolites. Some of those served as lead compounds for development of pharmaceuticals and agrochemicals. Recently, the endophytic Xylariales have also come in the focus of biological control, since some of their species show strong antagonistic effects against fungal and other pathogens. New compounds, including volatiles as well as nonvolatiles, are steadily being discovered from these ascomycetes, and polythetic taxonomy now allows for elucidation of the life cycle of the endophytes for the first time. Moreover, recently high-quality genome sequences of some strains have become available, which facilitates phylogenomic studies as well as the elucidation of the biosynthetic gene clusters (BGC) as a starting point for synthetic biotechnology approaches. In this review, we summarize recent findings, focusing on the publications of the past 3 years.

Indexed as

AscomycotaBiodiversityBiological ProductsSecondary MetabolismBiological Products

Identifiers

PMID33097836
PMCPMC7732752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.